Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of Amanita Muscaria Mushroom (AME-1) To Inhibit Human Mast Cell Activation Post published:October 19, 2021 Post category:Press Release
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies Post published:October 19, 2021 Post category:Press Release
First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial Post published:October 19, 2021 Post category:Press Release
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products Post published:October 19, 2021 Post category:Press Release
COMPASS Pathways is granted new US patent for crystalline psilocybin Post published:October 19, 2021 Post category:Press Release
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change Post published:October 19, 2021 Post category:Press Release
Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase to Psychedelics Production Quotas Post published:October 16, 2021 Post category:Psychedelic Bulletin
Psychedelic Research Bulletin: September 2021 Post published:October 16, 2021 Post category:Psychedelics Research Review
Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions Post published:October 14, 2021 Post category:Press Release
Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada Post published:October 14, 2021 Post category:Press Release